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Our case had hiccups arising in an adolescent with the attention deficit and hyperactivity disorder (ADHD) and conduct disorder 
(CD) after adding aripiprazole treatment to extended-release methylphenidate. Actually, antipsychotics are also used in the treat-
ment of hiccups, but studies suggest that they can cause hiccups as well. Within 12 hours of taking 2.5 mg aripiprazole added 
to extended-release methylphenidate at a dose of 54 mg/day, 16-year-old boy began having hiccups in the morning, which 
lasted after 3-4 hours. As a result, aripiprazole was discontinued and methylphenidate was continued alone because we could 
not convince the patient to use another additional drug due to this side effect. Subsequently, when his behavior got worsened 
day by day, his mother administered aripiprazole alone again at the dose of 2.5 mg/day at the weekend and continued treatment 
because hiccup did not occur again. But when it was administered with methylphenidate on Monday, hiccup started again next 
morning and lasted one hour at this time. In conclusion, we concluded that concurrent use of methylphenidate and aripiprazole 
in this adolescent led to hiccups. 
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INTRODUCTION
Hiccup is a repetitive, involuntary, spasmodic and char-
acteristic voice that can occur with closure of the glottis 
suddenly as a result of involuntary contraction of the dia-
phragm and respiratory muscles.1) Though the pathophy-
siological processes that lead to hiccups have not been 
completely established, central nervous system disorders, 
gastrointestinal disorders and tumors, metabolic and elec-
trolyte disorders and various drugs are implicated as caus-
es of hiccup.1) In drug-induced hiccups, aripiprazole is 
very often incriminated for transient and persistent hic-
cups among adult and adolescent patients.2,3) Here, we 
present a case of hiccups arising in adolescent with an ex-
tensive metabolizer genotype for CYP2D6 when using 
aripiprazole in addition to extended-release methylpheni-
date. Of note, his hiccups ceased when aripiprazole was 
used without methylphenidate.
CASE
The patient was a 16-year-old boy who was referred to 
the outpatient clinic with complaints of behavioral prob-
lems like difficulty in anger control, running away from 
school and home, smoking and telling lies. In his medical 
history, he was diagnosed with the attention deficit and 
hyperactivity disorder (ADHD) 5 years ago by a child and 
adolescent psychiatrist and received methylphenidate 54 
mg/day alone, with significant benefit for 5 years. But, 
within the last year, he started to fight, tell lies, smoke and 
also to be a school truant. Finally, it was learned that he 
took his father’s car without permission and had an acci-
dent with it. His family told that he did not have attention 
deficit problems during methylphenidate treatment and 
his academic achievement was satisfactory. In addition, 
he did not want to use methylphenidate anymore. In the 
psychiatric evaluation, he did not have eye contact and he 
told that he did not want to talk. He seemed very nervous. 
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And after ten minutes in silence, he shut the door hard and 
went out.
According to psychiatric assessment, he was diagnosed 
with ADHD and conduct disorder (CD) according to 
Diagnostic and Statistical Manual of Mental Disorders, 
fifth edition (DSM 5)4) and was prescribed aripiprazole 
2.5 mg/day adding to extended-release methylphenidate 
at a dose of 54 mg/day. Next day, he had an episode of hic-
cups in the morning starting 12 hours after the admin-
istration of first dose of 2.5 mg/day aripiprazole at night 
and hiccups lasted for 4 hours, which led him to come to 
clinic in great concern. He was extremely disturbed from 
this side effect. Therefore, we were unable to convince the 
patient to use another drug for behavioral problems. 
Owing to this side effect, it was thought that he may be a 
poor or intermediate metabolizer and pharmacogenetic 
testing was requested from medical genetics laboratory 
for CYP2D6. 
While waiting for test results, behavioral problems of 
the case were aggravated and his mother gave aripiprazole 
again at the dose of 2.5 mg/day for 2 weekend days saying 
that it was a vitamin for his lack of appetite, due to methyl-
phenidate because he had drug holidays for methyl-
phenidate every weekend. She told that she observed no 
hiccup with only aripiprazole but when she gave it again in 
weekdays in combination with methylphenidate, the hic-
cup started 12 hours later again and lasted for an hour at 
this time. She thought that he was better with aripiprazole 
when administered at alone, so at present patient is on only 
aripiprazole 5 mg/day as the schools are closed, and no 
hiccup is observed. Moreover, his behavioral problems 
decreased markedly. Meanwhile, our case was genotyped 
as extensive/normal metabolizer for CYP2D6. Evaluation 
with the Naranjo algorithm revealed a score of 7 (probably 
adverse drug reaction).5)
DISCUSSION
Here, we present a case of hiccups arising in a CYP2D6 
extensive/normal metabolizer adolescent who was using 
aripiprazole plus extended-release methylphenidate for 
the treatment of ADHD and CD. The use of atypical anti-
psychotics concomitantly with stimulants in children and 
adolescents is becoming more common as clinicians try to 
treat comorbidities involving ADHD, CD, oppositional 
defiant disorder, mental retardation and pediatric bipolar 
disorder despite their potentially opposing pharmaco-
logical mechanism.6,7)
Previous reports of hiccups with aripiprazole exist in 
the literature,2,3) but our case is of interest in that a drug 
used commonly in child psychiatry such as methyl-
phenidate promoted aripiprazole to cause hiccup. Although 
the precise roles of neurotransmitters within the reflex arc 
of hiccups remain to be completely understood, current 
data suggest that both dopamine and serotonin may play 
roles in the development of hiccups. Methylphenidate is 
currently the most commonly prescribed agent used to 
treat ADHD and it is thought to exert its effects by inhibit-
ing dopamine and norepinephrine reuptake and by bind-
ing the serotonin transporter.8,9) It is also used for the treat-
ment of hiccup in patients.10,11) 
Furthermore, aripiprazole, which is a partial agonist of 
dopamine 2,3 and 5-HT1A receptors, is used to stabilize 
dopamine and serotonin systems. Previous reports stated 
that both hypo- and hyper-dopaminergic states may give 
rise to hiccups and both drugs can lead to these conditions 
in our case.2,3)
The members of the cytochrome P450 protein family 
mediate the metabolism of many pharmaceutical agents 
and genetic variability in these enzymes may dictate a pa-
tient’s response to a drug. Identification of genotypes of 
these enzymes can minimize adverse drug reactions and 
improve patients’ response. CYP2D6 is the main cyto-
chrome P450 enzyme involved in the metabolism of anti-
psychotics and antidepressants.12) In our case, we utilized 
PGX-CYP2D6 Strip Assay (Vienna Lab Diagnostics, 
Vienna, Austria) to determine the genotype of CYP2D6. 
This test diagnoses patients as extensive/normal (two cop-
ies of wild-type alleles), poor (one wild-type allele plus 
one variant allele with reduced enzyme activity or two 
variant alleles with reduced enzyme activity) and ultra-
rapid metabolizer (multiple copies of wild-type alleles).13)
The patient was genotyped as extensive (normal) 
metabolizer. As a result, elimination of aripiprazole in-
volves two cytochrome P450 enzymes (CYP2D6, 
CYP3A4) and methylphenidate, which is both a substrate 
and a weak inhibitor of CYP2D6 at the same time, can lead 
to increased aripiprazole blood levels by blocking the me-
tabolism of aripiprazole or by competing with aripipra-
zole for CYP2D6 metabolism. Thus, aripiprazole can 
cause hiccup as seen in our case.
In conclusion, it is recommended that clinicians should 
take drug interactions into consideration when using more 
than one drug concurrently. Profiling cytochrome P450 
isoenzymes genotypes should be conducted in all patients 
prior to the onset of treatment when more than one drug is 
used in the same patient in order to benefit from treatment 
in the short term and to prevent side effects and drug 
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interactions.
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